Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Opioids are naturally or synthetically made in laboratories to mimic the chemical properties of opioids that interact with opioid receptors on the nerve cells in the body and brain and reduce pain. They are a class of drugs that include prescription pain relievers, synthetic opioids, and heroin. Prescription opioids are meant to be used to treat acute pain such as recovering from injury or post-surgery, chronic pain, active-phase cancer treatment, palliative care, and end-of-life care. Many people rely on prescription opioids to help manage their conditions under the care of a physician. Opioid use disorder is a chronic lifelong disorder, with serious potential consequences including disability, relapses, and death.

The global opioid use disorder market is estimated to be valued at US$ 2,739.2 million in 2021 and is expected to exhibit a CAGR of 8.7% over the forecast period (2021-2028)

Figure 1. Global Opioid Use Disorder Market Share (%), By Region, 2021

Opioid Use Disorder  | Coherent Market Insights

Increasing usage of buprenorphine patches as an effective treatment option for opioid use disorder is anticipated to drive the market growth over the forecast period

One of the upcoming trends witnessed in the global market in treating opioid addiction is the increasing usage of buprenorphine patches as an effective therapy for opioid use disorder. Buprenorphine patches are considered to be a novel approach for the treatment of opioid use disorder. The usage of transdermal patches has various advantages over other treatment modes such as injections as it is the most comfortable mode of drug delivery, which effectively reduces the pain and can be self-administered by the patient. Moreover, these buprenorphine patches can act as a potential alternative for patients requiring instant therapy for opioid use disorder.

For instance, in April 2020, WellSpan Health, a U.S.-based healthcare company, collaborated with York Opioid Collaborative, a public health and safety organizations, to establish a clinical trial and reached phase IV in the development of Lidocaine patch for the indication of opioid use disorder. This is expected to boost the adoption of treatment on a broader scale.  

request-sample

Opioid Use Disorder Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 2,739.2 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2028
Forecast Period 2021 to 2028 CAGR: 8.7% 2028 Value Projection: US$ 4,911.8 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type: Buprenorphine, Methadone, Naltrexone, Others
  • By Route of Administration: Oral, Parenteral
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, BioDelivery Sciences International Inc., Viatris Inc., Pfizer, Inc., Hikma Pharmaceuticals PLC, and Camurus

Growth Drivers:
  • Increasing usage of buprenorphine patches as an effective treatment option for opioid use disorder  
  • Increasing cases of opioid addiction
Restraints & Challenges:
  • Side effects that may arise from the drugs administered for the treatment of opioid addiction

Figure 2. Global Opioid Use Disorder Market Value (US$ Mn), By Drug Type, 2021

Opioid Use Disorder  | Coherent Market Insights

Increasing cases of opioid addiction is expected to drive the market growth over the forecast period

Rising number of patient population suffer from a wide range of severe and chronic diseases, such as cancer, cardiovascular disease, pain arising from injuries, and other conditions. These diseases often cause chronic pain that are managed with the consumption of painkillers, mostly opioids. While the pain reduces, there is a greater chance that the patient may get addicted to these drugs. The rising dependency of these drugs and abrupt discontinuation may lead to the patient suffering from withdrawal symptoms.

For instance, according to the World Health Organization’s report, about 0.5 million deaths are attributable to drug use globally. More than 70% of these deaths are related to opioids, with more than 30% of those deaths caused by overdose in 2020.

According to the Centre for Disease Control and Prevention report, opioids were involved in 49,860 overdose deaths in 2019 (70.6% of all drug overdose deaths) in the U.S.

Furthermore, according to the article published in the National Center for Biotechnology Information in July 2018, India has twice the global average prevalence of illicit opiate consumption. It is estimated that, India has about 4 million people who use opioids and around 1 million people who are opioid dependent in 2018.

Global Opioid Use Disorder Market – Impact of Coronavirus (Covid-19) Pandemic

The coronavirus pandemic has a varied impact on the pharmaceutical market, ranging from positive to negative, based on the demand. There has been a negative impact on certain medication, owing to a decline in their demand due to the lack of visits to the healthcare facilities such as hospitals and clinics. Furthermore, to decrease the number of coronavirus cases, several governments have implemented strict nationwide lockdown. This has led to sharp decline in the flow of patients across hospital settings. Moreover, the cancellation or postponement of non-essential medical procedures has further led to a negative impact on market growth.

However, the prominent companies engaged in the opioid use disorder market, such as Indivior PLC, experienced an overall decline in its product revenues during the pandemic. Thus, rapid decline in sales has occurred due to COVID-19 related disruption such as lockdown, lack of transportation, and others. Thus, the global opioid use disorder market is expected to experience a negative impact.

Global Opioid Use Disorder Market Restraint

One of the restraining factor that anticipated to limit the growth of the global market during the forecast period is the side effects that may arise from the drugs administered for the treatment of opioid addiction. Some of the typical adverse reaction from these drugs include vomiting, bladder pain, abdominal cramps, diarrhea, respiratory complications, bone or joint pain, muscle aches, and constipation. Furthermore, in certain severe cases of adverse reaction, the patient may also suffer from psychological problems such as depression.

Key Players

Major players operating in the global opioid use disorder market include Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, BioDelivery Sciences International Inc., Viatris Inc., Pfizer, Inc., Hikma Pharmaceuticals PLC, and Camurus.

Opioids, used medically for pain relief, have analgesic and central nervous system depressant effects as well as the potential to cause euphoria. Opioid use disorder (OUD) can involve misuse of prescribed opioid medications, use of diverted opioid medications, or use of illicitly obtained heroin. OUD is typically a chronic, relapsing illness, associated with significantly increased rates of morbidity and mortality. In patients with OUD who have achieved abstinence through medically supervised withdrawal or by other means, maintenance treatment aims to prevent relapse. Options for long-term maintenance treatment include an opioid agonist (i.e., methadone or buprenorphine), an opioid antagonist (naltrexone), or non-medication, abstinence-based treatment.

Market Dynamics

Increasing incidences of pain associated with chronic diseases such as cancer, rising cases of opioid addiction, and increasing adoption of inorganic growth strategies by key players in order to expand their product portfolio in the global opioid use disorder market. The general population nowadays suffers from a wide range of chronic and severe health conditions, such as pain arising from injuries or cancer. They often result in chronic pain and in such cases, patients are given painkillers, especially opioids. While they help in lowering pain, they can cause addiction among patients. The abrupt discontinuation or higher dependency on these drugs leads to withdrawal symptoms. This further increases the chances of fatal consequences, such as deaths.

For instance, The American Psychiatric Association (APA), stated that approximately 72,000 Americans died due to opioid overdose in 2017. These factors are likely to drive the opioid use disorder market growth in the near future.

Key features of the study:

  • This report provides in-depth analysis of the global opioid use disorder market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global opioid use disorder market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, BioDelivery Sciences International Inc., Viatris Inc., Pfizer, Inc., Hikma Pharmaceuticals PLC, and Camurus
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global opioid use disorder market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global opioid use disorder market

Detailed Segmentation:

  • Global Opioid Use Disorder Market, By Drug Type:
    • Buprenorphine
    • Methadone
    • Naltrexone
    • Others
  • Global Opioid Use Disorder Market, By Route of Administration:
    • Oral
    • Parenteral
  • Global Opioid Use Disorder Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Opioid Use Disorder Market, By Region:
    • North America
      • By Drug Type
        • Buprenorphine
        • Methadone
        • Naltrexone
        • Others
      • By Route of Administration
        • Oral
        • Parenteral
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Drug Type
        • Buprenorphine
        • Methadone
        • Naltrexone
        • Others
      • By Route of Administration
        • Oral
        • Parenteral
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Type
        • Buprenorphine
        • Methadone
        • Naltrexone
        • Others
      • By Route of Administration
        • Oral
        • Parenteral
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Type
        • Buprenorphine
        • Methadone
        • Naltrexone
        • Others
      • By Route of Administration
        • Oral
        • Parenteral
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Type
        • Buprenorphine
        • Methadone
        • Naltrexone
        • Others
      • By Route of Administration
        • Oral
        • Parenteral
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Type
        • Buprenorphine
        • Methadone
        • Naltrexone
        • Others
      • By Route of Administration
        • Oral
        • Parenteral
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Indivior PLC *
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Alkermes
    • Orexo AB
    • Titan Pharmaceuticals, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Mallinckrodt Pharmaceuticals
    • BioDelivery Sciences International Inc.
    • Viatris Inc.
    • Pfizer, Inc.
    • Hikma Pharmaceuticals PLC
    • Camurus

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Pipeline Analysis
    • PEST Analysis
    • Epidemiology
    • Regulatory Scenario
    • Reimbursement Scenario
    • Acquisitions and Collaboration
    • Brand Analysis
  4. Global Opioid Use Disorder Market - Impact of Coronavirus (COVID-19) Pandemic
    • Economic Impact
    • Impact on Opioid Use Disorder Market
    • Impact on Drug Development
  5. Global Opioid Use Disorder Market, By Drug Type, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Buprenorphine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Methadone
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Naltrexone
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  6. Global Opioid Use Disorder Market, By Route of Administration, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Parenteral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  7. Global Opioid Use Disorder Market, By Distribution Channel, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  8. Global Opioid Use Disorder Market, By Region, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, For Regions, 2018–2028
    • North America
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2017 – 2028, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Indivior PLC*
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Alkermes
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Orexo AB
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Titan Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Mallinckrodt Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • BioDelivery Sciences International Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Viatris Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Hikma Pharmaceuticals PLC
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Camurus
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 38 market data tables and 42 figures on "Opioid Use Disorder Market” - Global forecast to 2028

FAQgrowicon

Frequently Asked Questions

The global opioid use disorder market size is estimated to be valued at US$ 2,739.2 million in 2021 and is expected to exhibit a CAGR of 8.7% between 2021 and 2028.
Increasing usage of buprenorphine patches as an effective treatment option for opioid use disorder and increasing cases of opioid addiction are expected to drive the market growth over the forecast period.
Buprenorphine segment is expected to hold the major market share, owing to increasing product approvals and launches during the forecast period.
North America holds the largest market share in the market.
Major factors hampering growth of the market include the side effects that may arise from the drugs administered for the treatment of opioid addiction.
Major players operating in the market include Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, BioDelivery Sciences International Inc., Viatris Inc., Pfizer, Inc., Hikma Pharmaceuticals PLC, and Camurus.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.